Online inquiry

IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9868MR)

This product GTTS-WQ9868MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9868MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1979MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ4484MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ11399MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ4990MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ2390MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ3490MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ8686MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ14481MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO-7105705
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW